Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Microneedling for hair loss is discussed, with users mentioning using 0.6mm needles twice a week. Treatments like Minoxidil, finasteride, and RU58841 are implied but not directly mentioned.

The conversation discusses using RU58841, topical finasteride/minoxidil, MK677, and microneedling as treatments for hair loss. MK677 is mentioned as a growth hormone that improves hair health and recovery from microneedling.

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Amplifica's new injectable treatment for androgenetic alopecia shows a 15% increase in hair thickness and coarseness in 60 days. The treatment is in early human trials and offers a promising alternative to hormone-related hair loss treatments.

A user mixed a pyrilutamide solution and noticed undissolved powder at the bottom, questioning if this is normal and how long to wait before applying it. They wished others good luck with their treatments.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

The conversation discusses using a dermapen for microneedling to treat hair loss, with specific mention of using Minoxidil, Finasteride, Dutasteride, RU58841, KX-826, and other topicals. The user experienced side effects like palpitations and itching after microneedling and applying these treatments.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

The user is considering Botox for scalp hair loss and currently uses finasteride, minoxidil, microneedling, pumpkin seed oil, saw palmetto, and green tea extract. They seek information on potential risks and effectiveness.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.

The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Botox in scalp muscles is being discussed as a potential hair loss treatment. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

Dr. Kyle Gillet mentioned on Dr. Andrew Huberman's podcast that dutasteride mesotherapy blocks DHT conversion only in the scalp and is the most promising topical treatment. Users discussed concerns about systemic absorption and the practicality of dutasteride injections.

A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

Peptides are being discussed for potential hair loss treatments, but most are not proven effective for this purpose. Minoxidil and finasteride are mentioned as more reliable options for hair growth.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.